114 related articles for article (PubMed ID: 4038309)
21. Formulation of a potential antipregnancy vaccine based on the beta-subunit of human chorionic gonadotropin (beta-hCG). II. Use of compounds of the muramyl dipeptide (MDP) family as adjuvants.
Nash HA; Chang CC; Tsong YY
J Reprod Immunol; 1985 Feb; 7(2):151-62. PubMed ID: 3981488
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response.
Lowy I; Theze J; Chedid L
J Immunol; 1980 Jan; 124(1):100-4. PubMed ID: 6965289
[TBL] [Abstract][Full Text] [Related]
23. Immune response studies in relation to protection induced by using MDP as an adjuvant in malaria.
Khullar N; Gupta CM; Sehgal S
Immunol Invest; 1988 Mar; 17(1):1-17. PubMed ID: 3292412
[TBL] [Abstract][Full Text] [Related]
24. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Heymer B; Finger H; Wirsing CH
Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
[TBL] [Abstract][Full Text] [Related]
25. Carrier-induced epitope-specific regulation and its bypass in a protein-protein conjugate.
Kaliyaperumal A; Chauhan VS; Talwar GP; Raghupathy R
Eur J Immunol; 1995 Dec; 25(12):3375-80. PubMed ID: 8566026
[TBL] [Abstract][Full Text] [Related]
26. [Enhancement of the activity of hepatitis B virus vaccine by association with murabutide].
Audibert F; Przewlocki G; Lefrancier P; Choay J; Chedid L
C R Seances Acad Sci III; 1982 Nov; 295(10):611-4. PubMed ID: 6218866
[TBL] [Abstract][Full Text] [Related]
27. Antibody responses to a synthetic peptide-based malaria vaccine candidate: influence of sequence variants of the peptide.
Etlinger HM; Renia L; Matile H; Manneberg M; Mazier D; Trzeciak A; Gillessen D
Eur J Immunol; 1991 Jun; 21(6):1505-11. PubMed ID: 2044658
[TBL] [Abstract][Full Text] [Related]
28. Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity.
Arnon R; Sela M; Parant M; Chedid L
Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6769-72. PubMed ID: 6935684
[TBL] [Abstract][Full Text] [Related]
29. Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants.
Lussow AR; Del Giudice G; Rénia L; Mazier D; Verhave JP; Verdini AS; Pessi A; Louis JA; Lambert PH
Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2960-4. PubMed ID: 2183219
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).
Sugimoto M; Germain RN; Chedid L; Benacerraf B
J Immunol; 1978 Mar; 120(3):980-2. PubMed ID: 344799
[TBL] [Abstract][Full Text] [Related]
31. Effects of natural or synthetic microbial adjuvants on induction of autoimmune thyroiditis.
Kong YC; Audibert F; Giraldo AA; Rose NR; Chedid L
Infect Immun; 1985 Jul; 49(1):40-5. PubMed ID: 3839208
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative.
Parant M; Riveau G; Parant F; Chedid L
Am J Physiol; 1984 Sep; 247(3 Pt 1):C169-74. PubMed ID: 6476105
[TBL] [Abstract][Full Text] [Related]
33. Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.
Bahr GM; Tello DS; Chedid LA
Infect Immun; 1985 Aug; 49(2):312-9. PubMed ID: 4018873
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of immunoglobulin G responses in mice against hepatitis B virus surface antigen, influenza virus hemagglutinin vaccine, and tetanus toxoid by 6-O-acylated muramyl dipeptides.
Furuya T; Kumazawa Y; Takimoto H; Nagumo T; Watanabe M; Aizawa C; Kiso M; Hasegawa A; Nomoto K
Infect Immun; 1989 Jun; 57(6):1839-44. PubMed ID: 2722242
[TBL] [Abstract][Full Text] [Related]
35. Modulation of the immunosuppressive activity of CKS-17, a synthetic retroviral envelope peptide, by muramyl dipeptide.
Gauduin MC; Vogel FR; Simon JP; Audibert FA; Chedid LA
Viral Immunol; 1993; 6(3):175-83. PubMed ID: 8292225
[TBL] [Abstract][Full Text] [Related]
36. Synthetic peptide vaccine confers protection against murine malaria.
Zavala F; Tam JP; Barr PJ; Romero PJ; Ley V; Nussenzweig RS; Nussenzweig V
J Exp Med; 1987 Nov; 166(5):1591-6. PubMed ID: 3316473
[TBL] [Abstract][Full Text] [Related]
37. Immunization of owl monkeys with the ring-infected erythrocyte surface antigen of Plasmodium falciparum.
Collins WE; Anders RF; Ruebush TK; Kemp DJ; Woodrow GC; Campbell GH; Brown GV; Irving DO; Goss N; Filipski VK
Am J Trop Med Hyg; 1991 Jan; 44(1):34-41. PubMed ID: 1996739
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the antigenic relationship of various derivatives of n-acetyl-muramyl-l-ala-d-isoglutamine (MDP), using anti-MDP antibodies.
Bahr GM; Carelli C; Audibert F; Modabber F; Chedid L
Mol Immunol; 1982 May; 19(5):737-45. PubMed ID: 7110143
[TBL] [Abstract][Full Text] [Related]
39. Recent advances concerning the use of muramyl dipeptide derivatives as vaccine potentiators.
Audibert F; Chedid L
Prog Clin Biol Res; 1980; 47():325-38. PubMed ID: 7010376
[No Abstract] [Full Text] [Related]
40. Preparation for hapten help by glucan, muramyl dipeptide, and its L-ala-Glycerol-mycolate derivative.
Leech SH; Di Luzio NR; Leclerc C
J Leukoc Biol; 1985 Aug; 38(2):317-25. PubMed ID: 3861748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
